recombinant novel coronavirus vaccine (adenovirus type 5 vector)
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 24, 2020 (NCT04566770)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04566770 | Phase 2 | Sep 24, 2020 | Beijing Institute of Biotechnology, Government of China, Tianjin Cansino Biotechnology Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Institute of Biotechnology | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2020 |
| Tianjin Cansino Biotechnology Inc | For profit | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1